Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account
We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading
Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

R/R LBCL after ≥2 prior lines of systemic therapy ∨Select
Lymphoma
Type
Previously untreated Stage III/IV cHLPediatric previously untreated high-risk cHLcHL post-auto-HSCT consolidationRelapsed cHLR/R LBCL after ≥2 prior lines of systemic therapyPreviously untreated sALCL or other CD30-expressing PTCLRelapsed pcALCL or CD30-expressing MFRelapsed sALCLLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EfficacySafetyDosageMOA & Resources ∨MOA &
Resources
Patient ManagementMOA and CD30 TestingResourcesPatient Assistance
Prescribing InformationPatient InformationIndicationsLoadingPatient Site
EfficacyOverall SurvivalADCETRIS+R2 demonstrated a statistically significant OS benefit vs placebo+R2 alone*1,2 OS is time from randomization to death due to any cause. OS was estimated using the Kaplan-Meier method.2
First phase III randomized study to demonstrate a survival benefit in patients with R/R LBCL after ≥2 prior lines of systemic therapy1
OS Forest PlotConsistent OS was observed across the majority of prespecified subgroups2

This prespecified analysis was not powered to detect statistical significance. Only selected subgroups are highlighted.† These analyses are limited by small patient numbers. No conclusion about efficacy in the subgroups can be drawn from these data.

Prespecified subgroups not represented include race, region, prior HSCT.This was not a prespecified subgroup.This was a protocol prespecified stratification factor.Double- or triple-hit lymphoma is defined as rearrangements of MYC and BCL2 and/or BCL6.3Subsequent TherapySee data on subsequent therapyPatients who received subsequent therapy¶2 Subjects receiving multiple therapies are counted for each type of therapy and specific therapy received.Most common were acalabrutinib+durvalumab (n = 3 in placebo+R2), carboplatin+etoposide+ifosfamide (n = 1 in ADCETRIS+R2 and n = 2 in placebo+R2), lenalidomide (n = 1 in ADCETRIS+R2 and n = 2 in placebo+R2), and rituximab+gemcitabine+oxaliplatin (n = 1 in ADCETRIS+R2 and n = 2 in placebo+R2).ORRADCETRIS+R2 delivered an ORR of 64%, with 40% of patients achieving CR**1,5

Median time to response and median duration of complete response were post-hoc analyses. Median duration of response was a prespecified analysis. These analyses were not powered to detect statistical significance. No conclusion about efficacy can be drawn from these data.

ORR dataADCETRIS+R2 delivered an ORR of 64%, with 40% of patients achieving CR**1,5

Median time to response and median duration of complete response were post hoc analyses. Median duration of response was a prespecified analysis. These analyses were not powered to detect statistical significance. No conclusion about efficacy can be drawn from these data.

  • Median time to response for placebo+R2: 1.58 months (95% Cl: 0.7, 2.6) for any response, and 1.61 months (95% Cl: 0.7, 4.6) for CR2
  • Median duration of response for placebo+R2: 3.0 months (95% Cl: 2.8, 5.4) for any response, and NE (95% Cl: 2.8-NE) for CR2
Best response per Lugano 2014 by investigator assessment.4Two-sided P value based on stratified Cochran-Mantel-Haenszel test.1ReferencesNE = not evaluable; PR = partial response.
ORR by CD30 expressionORR observed with ADCETRIS+R2 by CD30 expression3

These subgroup analyses were not powered to detect statistical significance and are limited by small patient numbers. No conclusion about efficacy in the subgroups can be drawn from these data.

Best response per Lugano 2014 by investigator assessment.3
PFSProgression-free survivalADCETRIS+R2 significantly extended PFS vs placebo+R2 alone1 Median follow-up2:
  • ADCETRIS+R2: 11.1 months (95% CI: 8.6, 14.2)
  • Placebo+R2: 8.8 months (95% CI: 6.9, 10.9)
Median PFS2:
  • ADCETRIS+R2: 4.2 months (95% CI: 2.9, 7.1)
  • Placebo+R2: 2.6 months (95% CI: 1.4, 3.1)
HR <1 favors ADCETRIS+R2.3PFS is time from randomization to earliest occurrence or progressive disease, per Lugano 2014, or death. PFS was estimated using Kaplan-Meier method.2
Prior CAR T-Cell Treated SubgroupOS and ORR for patients with prior CAR-T cell therapyOS and ORR for a subgroup of patients treated with prior CAR-T cell therapy5

The ORR analysis was a post-hoc analysis. These subgroup analyses were not powered to detect statistical significance and are limited by small patient numbers. No conclusion about efficacy in the subgroups can be drawn from these data.

OS in patients who did not receive prior CAR T-cell therapy (HR 0.74; 95% CI: 0.49, 1.11)2:
  • ADCETRIS+R2 (n = 80) 6-month OS: 76.7%, and 12-month OS: 54.2%3
  • Placebo+R2 (n = 83) 6-month OS: 62.4%, and 12-month OS: 41.5%3
ORR in patients who did not receive prior CAR T-cell therapy3
  • ADCETRIS+R2 (n = 80): 63.8% (95% CI: 52.2, 74.2); 41.3% CR (95% CI: 30.4, 52.8); 22.5% PR
  • Placebo+R2 (n = 83): 48.2% (95% CI: 37.1, 59.4); 21.7% CR (95% CI: 13.4, 32.1); 26.5% PR
OS is time from randomization to death due to any cause.5HR and 95% CI based on an unstratified Cox regression model. HR <1 favors ADCETRIS+R2.5Best response per Lugano 2014 by investigator assessment.5
Elderly SubgroupOS and ORR in elderly patientsDemographics and disease characteristics of elderly patients6 High-grade B-cell lymphoma with translocations of MYC or BCL2 and/or BCL6.CD30 status per central result. When central result is not available, local result is used.Based on post-randomization corrected values.Refractory was defined as no response or a response lasting <6 months from the last treatment end date.CAR T = chimeric antigen receptor T-cell; LBCL-NOS = large B-cell lymphoma, not otherwise specified; ECOG = Eastern Cooperative Oncology Group;GCB = germinal center B cell; HSCT = hematopoietic stem cell transplantation; IPI = International Prognostic Index; LDH = lactate dehydrogenase.OS in elderly patients aged ≥65 and ≥75 years old‖‖‖

The ≥75 years old analysis was an exploratory post-hoc analysis. These subgroup analyses were not powered to detect statistical significance and are limited by small patient numbers. No conclusion about efficacy in the subgroups can be drawn from these data.

≥65 years old (n = 155)

OS in patients aged <65 (HR 0.88; 95% CI: 0.49, 1.56)2:
  • ADCETRIS+R2 (n = 33) 6-month OS: 61.5%, and 12-month OS: 42.0%3
  • Placebo+R2 (n = 42) 6-month OS: 53.3%, and 12-month OS: 40.1%3

≥75 years old (n = 86)

No clinically meaningful safety trends in patients aged ≥65 years and patients aged ≥75 years were identified.6

OS is time from randomization to death due to any cause.6HR and 95% CI based on an unstratified Cox regression model. HR <1 favors ADCETRIS+R2.6Best response per Lugano 2014 by investigator assessment.6ORR in elderly patients6

These analyses were post-hoc analyses and not powered to detect statistical significance. These analyses are limited by small patient numbers. No conclusions about efficacy in these subgroups can be drawn from these data.

ORR in patients <65 years3:
  • ADCETRIS+R2 (n = 16): 48.5% (95% CI: 30.8, 66.5); 27.3% CR (95% CI: 13.3, 45.5); 21.2% PR
  • Placebo+R2 (n = 14): 33.3% (95% Cl: 19.6, 49.5); 16.7% CR (95% CI: 7.0, 31.4); 16.7% PR
Best response per Lugano 2014 by investigator assessment.3
< Back R/R LBCL Home Loading
Up next >
Safety Loading
CI = confidence interval; CR = complete response; ORR = overall response rate; R/R DLBCL = relapsed or refractory diffuse large B-cell lymphoma.References:ADCETRIS Prescribing Information. Bothell, WA: Seagen Inc. Bartlett NL, Hahn U, Kim WS, et al. Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol. 2025. doi:10.1200/JCO-24-02242 Data on file. Pfizer Inc. Kim J, Hahn U, Kim W, et al. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: results from the phase 3 ECHELON-3 study. Abstract LBA7005. ASCO.Hahn U, Bartlett N, Kim JA, et al. Outcomes by refractory status and prior therapies received in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) from the ECHELON-3 study. Poster presented at: 66th American Society of Hematology (ASH) Annual Meeting; December 7-10, 2024; San Diego, CA.Bartlett N, Kim JA, Hahn U, et al. Outcomes in older patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) from the ECHELON-3 study. Poster presented at: 66th American Society of Hematology (ASH) Annual Meeting; December 7-10, 2024; San Diego, CA.
Available on this page:

Review Treatment Decision Guide for DLBCL

Download Guide Loading

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-A1T-USA-1084
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
Indications

ADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL

  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.

Previously untreated high risk cHL

  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

cHL post-auto-HSCT consolidation

  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.

Relapsed cHL

  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

Previously untreated sALCL or other CD30-expressing PTCL

  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Relapsed sALCL

  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.

Relapsed pcALCL or CD30-expressing MF

  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.

Relapsed and Refractory Large B-Cell Lymphoma (LBCL)

  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.

Important Safety Information

BOXED WARNING

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.

CONTRAINDICATION

Contraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).

WARNINGS AND PRECAUTIONS
Peripheral neuropathy (PN):
ADCETRIS causes PN that is predominantly sensory. Cases of motor PN have also been reported. ADCETRIS-induced PN is cumulative. Monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. Patients experiencing new or worsening PN may require a delay, change in dose, or discontinuation of ADCETRIS.

Anaphylaxis and infusion reactions: Infusion-related reactions (IRR), including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an IRR occurs, interrupt the infusion and institute appropriate medical management. If anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. Premedicate patients with a prior IRR before subsequent infusions. Premedication may include acetaminophen, an antihistamine, and a corticosteroid.

Hematologic toxicities: Fatal and serious cases of febrile neutropenia have been reported with ADCETRIS. Prolonged (≥1  week) severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS.

Administer G-CSF primary prophylaxis beginning with Cycle 1 for adult  patients who receive ADCETRIS in combination with chemotherapy for previously untreated Stage III/IV cHL or previously untreated PTCL or relapsed or refractory LBCL and pediatric patients who receive ADCETRIS in combination with chemotherapy for previously untreated high risk cHL.

Monitor complete blood counts prior to each ADCETRIS dose. Monitor more frequently for patients with Grade 3 or 4 neutropenia. Monitor patients for fever. If Grade 3 or 4 neutropenia develops, consider dose delays,  reductions, discontinuation, or G-CSF prophylaxis with subsequent doses.

Serious infections and opportunistic infections: Infections such as pneumonia, bacteremia, and sepsis or septic shock (including  fatal outcomes) have been reported in ADCETRIS-treated patients. Closely monitor patients during treatment for infections.

Tumor lysis syndrome: Patients with rapidly proliferating tumor and high tumor burden may be at increased risk. Monitor closely and take appropriate measures.

Increased toxicity in the presence of severe renal impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment. Avoid use in patients with severe renal impairment.

Increased toxicity in the presence of moderate or severe hepatic impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment. Avoid use in patients with moderate or severe hepatic impairment.

Hepatotoxicity: Fatal and serious cases have occurred in ADCETRIS-treated patients. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first ADCETRIS dose or rechallenge. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Monitor liver enzymes and bilirubin. Patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of ADCETRIS.

PML: Fatal cases of JC virus infection resulting in PML have been reported in ADCETRIS-treated patients. First onset of symptoms occurred at various times from initiation of ADCETRIS, with some cases occurring within 3 months of initial exposure. In addition to ADCETRIS therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. Consider PML diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. Hold ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is confirmed.

Pulmonary toxicity: Fatal and serious events of noninfectious pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported. Monitor patients for signs and symptoms, including cough and  dyspnea. In the event of new or worsening pulmonary symptoms, hold ADCETRIS dosing during evaluation and until symptomatic improvement.

Serious dermatologic reactions: Fatal and serious cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. If SJS or TEN occurs, discontinue ADCETRIS and administer appropriate medical therapy.

Gastrointestinal (GI) complications: Fatal and serious cases of acute pancreatitis have been reported. Other fatal and serious GI complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with preexisting GI involvement may increase the risk of perforation. In the event of new or worsening GI symptoms, including severe abdominal pain, perform a prompt diagnostic evaluation and treat appropriately.

Hyperglycemia: Serious cases, such as new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, and ketoacidosis (including fatal outcomes) have been reported with ADCETRIS. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Monitor serum glucose and if hyperglycemia develops, administer anti-hyperglycemic medications as clinically indicated.

Embryo-fetal toxicity: Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS. Advise male patients with female partners of reproductive potential to use effective contraception during ADCETRIS  treatment and for 4 months after the last dose of ADCETRIS.

ADVERSE REACTIONS
The most common adverse reactions (≥20%) in adult patients are  peripheral neuropathy, nausea, fatigue, musculoskeletal pain, constipation, diarrhea, vomiting, pyrexia, upper respiratory tract infection, mucositis, abdominal pain, and rash. The most common laboratory abnormalities (≥20%) in adult patients are decreased  neutrophils, increased creatinine, decreased hemoglobin, decreased lymphocytes, increased glucose, increased ALT, and increased AST. 

The most common Grade ≥3 adverse reactions (≥5%) in combination with AVEPC in pediatric patients were neutropenia, anemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection.

DRUG INTERACTIONS
Concomitant use of strong CYP3A4 inhibitors has the potential to affect  the exposure to monomethyl auristatin E (MMAE). Closely monitor adverse reactions.

USE IN SPECIAL POPULATIONS
Lactation: Breastfeeding is not recommended during ADCETRIS treatment.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.IndicationsADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL
  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
Previously untreated high risk cHL
  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
cHL post-auto-HSCT consolidation
  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
Relapsed cHL
  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
Previously untreated sALCL or other CD30-expressing PTCL
  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
Relapsed sALCL
  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.
Relapsed pcALCL or CD30-expressing MF
  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
Relapsed and Refractory Large B-Cell Lymphoma (LBCL)
  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.